Key Drivers
- High cash reserves
- Elevated SG&A
- Premium valuation
AIAI Summary
Tactile has shifted from a pure growth-at-a-premium story to a cash-generating, margin-recovery medical-device consolidator whose upside now hinges on sustained EBITDA-margin conversion and visible payer reimbursement wins rather than top-line acceleration alone. Monitor quarterly EBITDA-margin cadence and receivable days (reclaim above $28.5/RSI lift would validate the recovery; failure below $26 would signal material downside) to make actionable buy/sell decisions.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash reserves
- •Elevated SG&A
- •Premium valuation
TCMD shows strong liquidity and FCF generation but oversized operating expenses and a premium valuation that constrain net returns despite improving margins.
Price Behavior
Key Price Behavior Insights:
- •Below last month's avg
- •Oversold momentum
- •Support cluster near $26.1–$26.9
TCMD is in a short-term downtrend—closing at $26.10 well below last month's average (~$28.41) with an RSI near 25 (oversold), support around $26.1–$26.9 and resistance near $28.4 and $29.3–$30.2.
Close at $26.10 significantly below last month's average (~$28.41) with
Sentiment & News
Key News Insights:
- •Estimate revisions
- •Rising price targets
- •Board strengthening
Analysts have materially reappraised Tactile Systems (TCMD), with upward earnings-estimate revisions, rising implied upside (≈28%→≈41%), and a board appointment bolstering governance.
The improving analyst sentiment and governance signal increase upside potential and investor confidence in TCMD, supporting share-price appreciation absent disappointing results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings